Dogwood Therapeutics, Inc (NASDAQ:DWTX) Stock Short Interest Climbs 60.4%

by · The Markets Daily

Dogwood Therapeutics, Inc (NASDAQ:DWTX – Get Free Report) saw a large increase in short interest in October. As of October 15th, there was short interest totaling 62,406 shares, an increase of 60.4% from the September 30th total of 38,895 shares. Based on an average daily volume of 76,074 shares, the short-interest ratio is currently 0.8 days. Currently, 0.2% of the shares of the stock are sold short.

Dogwood Therapeutics Stock Performance

DWTX traded down $0.03 during trading on Monday, reaching $1.25. The company had a trading volume of 35,088 shares, compared to its average volume of 75,986. The firm’s 50-day simple moving average is $1.68 and its 200 day simple moving average is $1.99. The company has a market cap of $42.49 million, a price-to-earnings ratio of -0.14 and a beta of 2.08. Dogwood Therapeutics has a 12-month low of $1.07 and a 12-month high of $7.04.

Dogwood Therapeutics (NASDAQ:DWTX – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.20). On average, sell-side analysts expect that Dogwood Therapeutics will post -0.80 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently commented on DWTX. Weiss Ratings reissued a “sell (e+)” rating on shares of Dogwood Therapeutics in a research note on Thursday, October 22nd. HC Wainwright restated a “buy” rating on shares of Dogwood Therapeutics in a research report on Wednesday, September 2nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Dogwood Therapeutics presently has an average rating of “Hold” and a consensus target price of $12.00.

Check Out Our Latest Stock Report on Dogwood Therapeutics

About Dogwood Therapeutics

(Get Free Report)

Dogwood Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for diseases associated with viral activation. The company’s programs are designed to address conditions for which persistent or reactivated viral activity may contribute to symptoms and disease progression.

Its lead investigational product, IMC-1, is an oral combination of the antiviral drug famciclovir and the anti-inflammatory drug celecoxib. The company has evaluated IMC-1 in fibromyalgia and has also investigated its potential use in other conditions, including symptoms associated with long COVID.

See Also